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7 ABSTRACT: Mutation of a gatekeeper residue, tryptophan 37, in E. coli lipoic acid ligase (LplA), expands substrate specificity
8 such that unnatural probes much larger than lipoic acid can be recognized. This approach, however, has not been successful for
9 anionic substrates. An example is the blue fluorophore Pacific Blue, which is isosteric to 7-hydroxycoumarin and yet not
10 recognized by the latter’s ligase (W37VLplA) or any tryptophan 37 point mutant. Here we report the results of a structure-guided,
11 two-residue screening matrix to discover an LplA double mutant, E20G/W37TLplA, that ligates Pacific Blue as efficiently as W37VLplA
12 ligates 7-hydroxycoumarin. The utility of this Pacific Blue ligase for specific labeling of recombinant proteins inside living cells, on
13 the cell surface, and inside acidic endosomes is demonstrated.
14 Probe incorporation mediated by enzymes (PRIME) is a15 method to tag recombinant proteins in living cells with
16 chemical probes. The method utilizes mutants of E. coli lipoic
17 acid ligase (LplA), whose natural function is to ligate lipoic acid
18 onto acceptor proteins involved in oxidative metabolism.1
19 Instead of lipoic acid, LplA mutants catalyze the covalent
20 attachment of unnatural chemical probes, such as 7-
21 hydroxycoumarin,2 an aryl azide,3 or an alkyl azide,4 onto
22 recombinant proteins fused to a 13-amino acid recognition
23 sequence called LAP (LplA acceptor peptide).5 The advantages
24 of PRIME in comparison to other protein labeling methods are
25 the small tag size, compatibility with the interior of living cells,
26 and high labeling specificity.6
27 In previous studies, uptake of the unnatural substrate by LplA
28 was achieved by mutation of a “gatekeeper” residue, W37, at the
f1 29 end of the lipoic acid binding pocket (Figure 1B). Enlarging
30 this pocket, for example by a W37 → V mutation, allows LplA
31 to accept structures much larger than lipoic acid, such as the
32 blue fluorophore 7-hydroxycoumarin (HC)2 (Figure 1A, top).
33 In the course of our screening, however, we discovered several
34 structures that are not accepted by W37 point mutants. One of
35 the most interesting examples is Pacific Blue (PB),7 a
36 fluorophore that differs from HC only in the two fluorine
37 atoms at C6 and C8 of the coumarin ring (Figure 1A, bottom).
38 Because of these two electron-withdrawing fluorines, PB has a
39 reduced 7-hydroxyl pKa of 3.7, compared to 7.5 for HC,
7 and is
40 therefore fully anionic and fluorescent at physiological pH (7.4)
41as well as endosomal pH (5.5−6.5). In contrast, only ∼50% of
42HC is in the anionic and fluorescent form at pH 7.4, and it is
43mostly protonated and hence nonfluorescent in acidic endo-
44somes.
45We hypothesized that PB is not recognized by HC’s ligase,
46
W37VLplA, and other W37 point mutants because its negative
47charge clashes with the mostly hydrophobic binding pocket of
48LplA.8 In addition, near the W37 gatekeeper residue at the end
49of the lipoic acid binding tunnel is a negatively charged side
50chain, E20, that may electrostatically repel PB8 (Figure 1B).
51E20 could play a steric role as well, since a previous alanine scan
52in the lipoate binding pocket identified E20A as one of two
53mutants (along with W37A) with any detectable ligation
54activity for an aryl azide probe.3
55The goal of this work was to use PB as a model compound to
56explore strategies for engineering new LplA activity, such as
57recognition of anionic substrates, beyond point mutations at
58W37. A PB ligase is also a useful alternative to HC ligase for
59studying proteins in acidic cellular compartments, where HC
60fluorescence is very low. By performing in-vitro screens using a
61panel of E20 and W37 single and double mutants, we
62discovered that E20G/W37TLplA ligates PB with comparable
63kinetics to W37VLplA ligation of HC (Figure 1A). We
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64 demonstrated the utility of our PB ligase for in-vitro, cell
65 surface, and intracellular site-specific protein labeling.
66 ■ EXPERIMENTAL PROCEDURES
67 Plasmids. The LplA-pYJF16 plasmid was used for bacterial
68 expression of LplA.2
69 The LplA-pcDNA3 plasmid was used for mammalian
70 expression of LplA.2 For mammalian expression of LAP fusion
71 proteins, LAP-YFP-NLS-pcDNA3, LAP4.2-neurexin-1β-
72 pNICE, and vimentin-LAP in Clontech vector were used and
73 have been described.2,9 The LAP sequence used was
74 GFEIDKVWYDLDA. For some constructs (neurexin and
75 LDL receptor), an alternative peptide sequence called LAP4.2
76 was used instead (GFEIDKVWHDFPA).5 LAP4.2-LDLR-
77 pcDNA4 was generated from HA-LDLR-pcDNA410 by a
78 two-stage QuikChange to insert the LAP4.2 sequence and
79 was a gift from Daniel Liu (MIT). The nuclear YFP
80 transfection marker was H2B-YFP and has been described.11
81 All mutants were prepared by QuikChange mutagenesis.
82 LplA Expression and Purification. LplA mutants were
83 expressed in BL21 E. coli and purified by His6-nickel affinity
84 chromatography as previously described.2
85 f2In-Vitro Screening of LplA Mutants (Figure 2A).
86Ligation reactions were assembled as follows for Figure 2A: 2
87μM purified LplA mutant, 150 μM synthetic LAP peptide
88(GFEIDKVWYDLDA; synthesized by the Tufts Peptide
89Synthesis Core Facility), 5 mM ATP, 500 μM fluorophore
90probe, 5 mM magnesium acetate, and 25 mM Na2HPO4 pH 7.2
91in a total volume of 25 μL. Reactions were incubated for 12 h at
9230 °C.
93LplA mutant/probe combinations giving high activity under
94these conditions were then reassayed with 10-fold lower probe
95(50 μM) for 2 h.
96Product formation was analyzed by ultraperformance liquid
97chromatography (UPLC) on a Waters Acquity instrument
98using a reverse-phase BEH C18 column 1.7 μM (1.0 × 50 mm)
99with inline mass spectroscopy. Chromatograms were recorded
100at 210 nm. A gradient of 30−70% (acetonitrile + 0.05%
101trifluoroacetic acid) in (water with 0.1% trifluoroacetic acid)
102over 0.78 min was used.
103Further in-Vitro Screening of Top Five LplA Double
104Mutants (Figure 2B,C). Reactions for the top five LplA
105double mutants were assembled as above, but with 500 μM
106probe and a reaction time of 45 min. Reactions were quenched
107with EDTA to a final concentration of 100 mM. Product
108formation was analyzed on a Varian Prostar HPLC using a
109reverse-phase C18 Microsorb-MV 100 column (250 × 4.6
110mm). Chromatograms were recorded at 210 nm. We used a 10
111min gradient of 30−60% acetonitrile in water with 0.1%
112trifluoroacetic acid under 1 mL/min flow rate. Percent
113conversions were calculated by dividing the product peak area
114by the sum of (product + starting material) peak areas.
115Michaelis−Menten Kinetic Assay. The Michaelis−Ment-
116en curve shown in Figure S4 was generated as previously
117described.2 Reaction conditions were as follows: 2 μM
118
E20G/W37TLplA, 600 μM synthetic LAP peptide, 2 mM
119magnesium acetate, and 25 mM Na2HPO4 pH 7.2.
120Mammalian Cell Culture and Imaging. HEK and HeLa
121cells were cultured in growth media consisting of Minimum
122Essential Medium (MEM, Cellgro) supplemented with 10%
123fetal bovine serum (FBS, PAA Laboratories). Cells were
124maintained at 37 °C under 5% CO2. For imaging, HEK cells
125were grown on glass coverslips pretreated with 50 μg/mL
126fibronectin (Millipore) to increase their adherence.
127Cells were imaged in Dulbecco’s Phosphate Buffered Saline
128 f3f4(DPBS) at room temperature. The images in Figures 3 and 4
129were collected on a Zeiss AxioObserver.Z1 microscope with a
13040× oil-immersion objective and 2.5× Optovar, equipped with
131a Yokogawa spinning disk confocal head containing a Quad-
132band notch dichroic mirror (405/488/568/647 nm). Pacific
133Blue/coumarin (405 nm laser excitation, 445/40 emission
134filter), YFP (491 nm laser excitation, 528/38 emission filter),
135Alexa Fluor 568 (561 nm laser excitation, 617/73 emission
136filter), and DIC images were collected using Slidebook software
137(Intelligent Imaging Innovations). Images were acquired for
138100 ms to 1 s using a Cascade II:512 camera. Fluorescence
139images in each experiment were normalized to the same
140intensity range.
141Cell Surface Labeling. HEK cells were transfected with
142200 ng of LAP4.2-LDLR-pcDNA4 and 100 ng of H2B-YFP
143cotransfection marker plasmid, per 0.95 cm2 at ∼70%
144confluency, using Lipofectamine 2000 (Invitrogen). Fifteen
145hours after transfection, the growth media was removed, and
146the cells were washed three times with DPBS. The cells were
Figure 1. Engineering a Pacific Blue (PB) ligase. (A) Fluorophore
ligations catalyzed by mutants of lipoic acid ligase (LplA). The top row
shows ligation of 7-hydroxycoumarin (HC) by W37VLplA onto a LAP
(LplA acceptor peptide)5 fusion protein, demonstrated in previous
work.2 The bottom row shows ligation of PB by E20G/W37TLplA,
demonstrated in this work. (B) Cut-away view of wild-type LplA in
complex with lipoyl-AMP ester, the intermediate of the natural ligation
reaction. Adapted from PDB ID 3A7R.8 W37 and E20 side chains are
highlighted. (C) Modeled structure of E20G/W37TLplA in complex with
PB-AMP ester. The PB-AMP conformation was energetically
minimized using Avogadro.13
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147labeled by applying 100 μM Pacific Blue or hydroxycoumarin
148probe, 2 μM ligase, 1 mM ATP, and 5 mM Mg(OAc)2 in DPBS
149at room temperature for 40 min. Cells were then washed three
150times with DPBS and either imaged immediately or incubated
151at 37 °C for an additional 30 min to allow receptor
152internalization prior to imaging.
153Intracellular Protein Labeling. HEK cells were trans-
154fected at ∼70% confluency with 200 ng of LAP-YFP-NLS-
155pcDNA3 and 50 ng of FLAG-E20G/W37TLplA-pcDNA3 per 0.95
156cm2 using Lipofectamine 2000 (Invitrogen). Fifteen hours after
157transfection, the growth media was removed, and the cells were
158washed three times with serum-free MEM. The cells were
159labeled by applying 20 μM PB3-AM2 in serum-free MEM at 37
160°C for 20 min. The cells were then washed three times with
161fresh MEM. Excess probe was removed by changing the media
162several times over 40 min.
163To visualize LplA expression levels, cells were fixed using
1643.7% formaldehyde in PBS pH 7.4 for 10 min, followed by
165methanol at −20 °C for 5 min. Fixed cells were washed with
166DPBS and then blocked overnight with blocking buffer (3%
167BSA in DPBS with 0.1% Tween-20). Anti-FLAG M2 antibody
168(Sigma) was added at a 1:300 dilution in blocking buffer for 1 h
169at room temperature. Cells were then washed three times with
170DPBS before treatment with a 1:300 dilution of goat anti-
171mouse antibody conjugated to Alexa Fluor 568 (Invitrogen) in
172blocking buffer for 1 h at room temperature. Cells were washed
173three times with DPBS prior to imaging.
174For labeling of vimentin-LAP (Figure 4B), HeLa cells were
175transfected with 250 ng of vimentin-LAP-Clontech, 50 ng of
176FLAG-E20G/W37TLplA-pcDNA3, and 100 ng of H2B-YFP
177transfection marker per 0.95 cm2 using Lipofectamine 2000.
178Labeling was performed as above, with an extended 60 min
179washout period to remove excess probe. Cells were then
180imaged live in DPBS.
181We note that, compared to intracellular labeling with
182hydroxycoumarin, labeling with PB3 generally requires longer
183washout times, up to 60 min in some cases. Shorter wash times
184result in higher PB background in all cells.
185■ RESULTS
186Screening for a Pacific Blue Ligase. On the basis of the
187LplA crystal structure (Figure 1B),8 we decided to focus our
188engineering efforts on the W37 and E20 positions. We started
189with a preliminary screen of 19 W37 point mutants and 14 E20
190point mutants, against four probe structures (Figure S1). These
191four structures, shown in Figure 2A, are two Pacific Blue probes
192with shorter (n = 3) and longer (n = 4) linkers (PB3 and PB4)
193and two analogous 7-hydroxycoumarin probes (HC3 and
194HC4). Some Pacific Blue (PB) ligation product was detected
195after a 12 h reaction with W37T, V, I, and A LplA mutants
196(Figure S1), so we decided to introduce these mutations into
197our next screen. Note that the activity of the best point mutant,
198
W37TLplA, which gave ∼50% conversion to PB ligation product
199after 12 h, is too slow for practical utility. For E20, none of the
200tested point mutants gave product with any of the four probes
201after 12 h. Nevertheless, in our next screen, we included E20
202mutations to the smaller, neutral side chains Gly, Ala, and Ser.
203Our next library consisted of 7 single mutants (four at W37
204and three at E20) and their 12 crossed double mutants, shown
205in Figure 2A. Screening was performed using 500 μM probe in
206an overnight reaction. Any ligase/probe combination with high
207activity under these conditions was reassayed using 50 μM
Figure 2. Screening of LplA mutants for Pacific Blue ligation activity.
(A) Relative product conversions measured for 19 LplA single and
double mutants with two hydroxycoumarin (HC) probes and two
Pacific Blue (PB) probes. HC3 and PB3 have n = 3 linkers, and HC4
and PB4 have n = 4 linkers. To generate these grids, ligation reactions
were performed under both forcing conditions (12 h, 500 μM probe)
and milder conditions (2 h, 50 μM probe) and analyzed by
ultraperformance liquid chromatography, as described in the
Experimental Procedures. Sample traces are shown in Figure S2.
The activity grid was generated with the following tiers: no activity,
<25% conversion in a 12 h reaction, 25−50% conversion in a 12 h
reaction, <25% conversion in 2 h reaction, 25−50% conversion in 2 h
reaction, >50% conversion in 2 h reaction. (B) Quantitative product
yields for the top five PB ligases in (A), after 45 min reaction with 500
μM of each probe. N.D. indicates not detected. The best LplA mutants
for PB3, HC3, and HC4 are highlighted. Errors are reported as
standard errors of the mean. (C) HPLC trace showing formation of
LAP-PB3 conjugate, catalyzed by our best PB ligase, E20G/W37TLplA.
The identity of the LAP-PB3 peak was confirmed by mass
spectrometry, shown in Figure S3. Traces below show negative
control reactions with ATP omitted (red) or E20G/W37TLplA replaced
by wild-type LplA (black).
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208 probe in a 2 h reaction. As before, the E20 single mutants had
209 no detectable activity (Figure 2A). The W37 single mutants
210 were minimally active with both PB probes, although high
211 activity was seen with HC3 and HC4. The best single mutant/
212 probe pair was W37VLplA with HC4.
213 The LplA double mutants, however, had interesting patterns
214 of activity with PB. Although none of the mutants ligated PB4
215 efficiently, PB3 was ligated well by five double mutants (Figure
216 2A; re-evaluated quantitatively in Figure 2B). The best two
217 have the W37T mutation, suggesting that not only size
218 reduction but also polarity increase at this position is beneficial
219for PB recognition. We noticed that the W37A mutation
220performed poorly in the context of all double mutants for all
221four probes, perhaps because it destabilizes the binding pocket.
222The best E20 mutation to pair with W37T was Gly, perhaps
223because it generates the most space and conformational
224freedom. Together, our observations suggest that W37 and
225E20 mutations work synergistically to allow PB uptake: W37
226mutations enlarge the binding pocket, while E20 mutations
227remove repulsive electrostatic interactions (Figure 1C).
228We proceeded to fully characterize our best PB ligase to
229emerge from this screen, E20G/W37TLplA. First, HPLC analysis of
230the ligation reaction was repeated (Figure 2C), alongside
231negative controls omitting ATP or replacing PB ligase with
232wild-type LplA. Second, the kinetic constants for PB3 ligation
233to LAP were measured by HPLC (Figure S4). Both kcat (0.014
234± 0.001 s−1) and KM (17.5 ± 4.3 μM) values are comparable to
235those previously determined for HC4 ligation catalyzed by
236
W37VLplA (kcat 0.019 ± 0.004 s
−1 and KM 56 ± 20 μM).
2 Finally,
237we tested the sequence specificity of PB3 ligation by labeling a
238LAP fusion protein within mammalian cell lysate. Figure S5
239shows that only LAP is labeled by PB ligase and not any
240endogenous mammalian proteins.
241Cell Surface Labeling with Pacific Blue Ligase. To test
242our PB ligase on living cells, we first performed labeling of a cell
243surface protein. The neuronal adhesion protein neurexin-1β
244with LAP4.2 (a variant of LAP5 whose sequence is given in the
245Experimental Procedures) fused to its extracellular N-terminus
246was expressed in human embryonic kidney (HEK) cells.
247Labeling was performed by adding purified PB ligase, PB3
248probe, and ATP to the cellular media for 30 min. Figure S6
249shows a ring of PB fluorescence around cells expressing
250LAP4.2-neurexin, as indicated by the presence of the
251cotransfection marker, whereas untransfected neighboring
252cells are not labeled. Negative controls performed with wild-
253type LplA, ATP omitted, or an alanine mutation in LAP
254resulted in no visible labeling (Figure S6).
255A potential advantage of PB ligase over HC ligase is for
256visualization of proteins in acidic organelles, where HC
257fluorescence is low due to its pKa of 7.5. To test this
258experimentally, we used PB ligase or HC ligase to label LAP4.2-
259LDL receptor (low-density lipoprotein receptor) on the surface
260of HEK cells. After labeling, cells were incubated for 30 min at
26137 °C to allow internalization of fluorescently tagged receptors.
262Figure 3 shows that PB-tagged LAP4.2-LDL receptor is clearly
Figure 3. Cell surface labeling with Pacific Blue ligase and imaging of internalized protein pools. HEK cells expressing LAP4.2-LDL receptor were
labeled at the cell surface with either PB ligase and PB3, or HC ligase and HC4, for 40 min at room temperature. Cells were then imaged
immediately (left side; 0 min internalization) or incubated for an additional 30 min at 37 °C to allow internalization of labeled LAP4.2-LDL receptor
before imaging (right side). Pacific Blue and hydroxycoumarin channels are shown. Nuclear YFP was a cotransfection marker. All scale bars: 10 μm.
Figure 4. Intracellular protein labeling with Pacific Blue ligase. (A)
HEK cells expressing LAP-YFP-NLS (NLS is a nuclear localization
signal) and PB ligase (E20G/W37TLplA) were treated with PB3-AM2 for
20 min, washed for 40 min, fixed with formaldehyde, and stained with
anti-FLAG antibody to detect FLAG-tagged LplA. Images show PB
labeling of transfected YFP-positive and FLAG-positive cells. The
second row is a negative control with PB ligase replaced by wild-type
LplA. The third row is a negative control with LAP-YFP-NLS replaced
by a point mutant with a K → A mutation in LAP. (B) HeLa cells
expressing vimentin-LAP and PB ligase (E20G/W37TLplA) were labeled
with PB3-AM2 for 20 min, washed for 60 min, and then imaged live.
Scale bars: 10 μm.
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263 visible within internalized puncta, whereas HC-tagged LAP4.2-
264 LDL receptor is not. Separate experiments showed that many
265 of the PB-labeled internal puncta overlap with FM4-64, an
266 endosomal marker (data not shown).
267 Intracellular Protein Labeling with Pacific Blue
268 Ligase. We tested PB ligase for labeling of intracellular
269 proteins in living mammalian cells. To deliver PB3 across the
270 cell membrane, we first protected the carboxylic acid and 7-
271 hydroxyl groups of PB3 with acetoxymethyl (AM) groups to
272 give PB3-AM2 (structure shown in Supporting Information).
273 Endogenous intracellular esterases remove the AM groups to
274 give PB3 inside the cell.12 HEK cells were cotransfected with
275 plasmids for PB ligase and LAP-YFP-NLS (NLS is a nuclear
276 localization signal; YFP is yellow fluorescent protein). To
277 perform labeling, PB3-AM2 was incubated with cells for 20 min,
278 and then the media was replaced 3 times over 40 min to allow
279 cells to pump out excess, unconjugated probe. The cells were
280 then fixed, and anti-FLAG immunostaining was performed to
281 visualize enzyme expression. As expected for specific labeling,
282 PB fluorescence overlaps well with the YFP fluorescence of
283 LAP-YFP-NLS (Figure 4). PB is not seen in neighboring
284 untransfected cells. PB labeling is also absent when wild-type
285 LplA is used in place of PB ligase, or the LAP-YFP-NLS
286 contains a Lys → Ala mutation in the LAP sequence. To
287 illustrate generality, we also performed PB labeling in live cells
288 of vimentin-LAP, an intermediate filament protein (Figure 4B).
289 ■ DISCUSSION
290 In this study, we identified an LplA double mutant capable of
291 recognizing and ligating a charged probe, Pacific Blue. Unlike
292 previous studies where simple enlargement of the binding
293 pocket via a point mutation at W37was sufficient to allow
294 recognition of large hydrophobic probes, the synergistic effect
295 of mutating both the E20 and W37 positions was required for
296 recognition of Pacific Blue. Guided by the LplA crystal
297 structure, we were able to create a small and focused library
298 of single and double LplA mutants to screen for the desired PB
299 ligation activity. No single mutation had significant activity, but
300 the augmentation of the most active W37 single mutants by
301 E20 mutations resulted in a kinetically efficient PB ligase. We
302 anticipate that these insights into the substrate binding pocket
303 of LplA will prove useful in future engineering efforts. The
304 engineered PB ligase has kcat and KM values similar to those of
305 our previously reported 7-hydroxycoumarin ligase.2 PB ligase
306 also retained sequence specificity for LAP over all endogenous
307 mammalian proteins and could therefore be used for specific
308 protein labeling inside and on the surface of living mammalian
309 cells.
310 With this report, PRIME labeling can now be performed with
311 any of three coumarin probes: Pacific Blue, 7-hydroxycoumar-
312 in,2 or 7-aminocoumarin (AC).9 The decision of which
313 coumarin to use is dependent on the specific application. HC
314 is the brightest of the three probes, followed by PB and then
315 AC due to its decreased extinction coefficient.7,9 However, as
316 demonstrated here, PB and AC have the added benefit of pH
317 insensitivity, whereas the pKa of HC makes it unsuitable for
318 imaging in acidic organelles such as endosomes.
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